Epstein-Barr-virus-associated hepatitis with aplastic anemia: A case report

Area of Science:

• Hematology
• Virology
• Immunology

Background:

• Hepatitis-associated aplastic anemia (HAAA) is a rare, often fatal condition characterized by acute hepatitis followed by bone marrow failure.
• Epstein-Barr virus (EBV) is a rare but implicated cause of HAAA, with limited documented cases.
• HAAA presents with jaundice, elevated transaminases, and subsequent severe or extremely severe aplastic anemia.

Observation:

• A 30-year-old male presented with jaundice, pale urine, and pancytopenia.
• Diagnosis was confirmed as Epstein-Barr virus-associated HAAA.
• The patient exhibited progressive hemocytopenia and bone marrow failure.

Findings:

• The patient received a treatment regimen including eltrombopag, rabbit anti-human thymocyte immunoglobulin, and cyclosporine.
• Supportive care was administered alongside the primary treatment.
• After five months of treatment, the patient achieved a complete hematological response and was discharged in good condition.

Implications:

• This case suggests that eltrombopag combined with immunosuppressive therapy may be a viable treatment option for EBV-associated HAAA.
• Further research and larger studies are necessary to validate this therapeutic approach for EBV-HAAA.
• This highlights a potential therapeutic strategy for a rare and life-threatening condition.